Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii

Batista-Duharte, Alexander; Lastre, Miriam; Romeu, Belkis; Portuondo, Deivys Leandro; Téllez-Martínez, Damiana; Manente, Francine Alessandra; Pérez, Oliver; Carlos, Iracilda Zeppone

doi:10.1016/j.intimp.2016.09.008

Cited by 24 publications

(17 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to the free drug, AFCo3-AmB showed enhanced antifungal efficacy in vitro and reduced cytotoxicity against peritoneal macrophages and murine erythrocytes. This formulation showed improved fungicidal activity against intracellular yeast in peritoneal macrophages and stimulated ex vivo release of pro-inflammatory mediators from splenocytes [196]. In vivo, AFCo3-AmB was also more effective than the native drug at reducing spleen and liver fungal load after i.p.…”

Section: Cochleatesmentioning

confidence: 94%

“…in a mouse model of systemic sporotrichosis and induced Th1/Th17 response with no significant changes in BUN and serum creatinine levels. [196] Nanodisk (ND)…”

Section: Lipid Conjugatesmentioning

confidence: 99%

“…A novel cochleate formulation containing detoxified LPS from Neisseria meningitides B as a pathogen-associated molecular pattern for immunomodulating properties has recently been developed for the treatment of sporotrichosis [196]. Adjuvant Finlay Cochleate 3 (AFCo3), acting as a vaccine adjuvant and drug delivery agent for AmB, has been evaluated for its immunomodulatory and antifungal activities against Sporothrix schenckii [196]. Compared to the free drug, AFCo3-AmB showed enhanced antifungal efficacy in vitro and reduced cytotoxicity against peritoneal macrophages and murine erythrocytes.…”

Section: Cochleatesmentioning

confidence: 99%

See 2 more Smart Citations

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

2020

View full text Add to dashboard Cite

Amphotericin B (AmB), a broad-spectrum polyene antibiotic in the clinic for more than fifty years, remains the gold standard in the treatment of life-threatening invasive fungal infections and visceral leishmaniasis. Due to its poor water solubility and membrane permeability, AmB is conventionally formulated with deoxycholate as a micellar suspension for intravenous administration, but severe infusion-related side effects and nephrotoxicity hamper its therapeutic potential. Lipid-based formulations, such as liposomal AmB, have been developed which significantly reduce the toxic side effects of the drug. However, their high cost and the need for parenteral administration limit their widespread use. Therefore, delivery systems that can retain or even enhance antimicrobial efficacy while simultaneously reducing AmB adverse events are an active area of research. Among those, lipid systems have been extensively investigated due to the high affinity of AmB for binding lipids. The development of a safe and cost-effective oral formulation able to improve drug accessibility would be a major breakthrough, and several lipid systems for the oral delivery of AmB are currently under development. This review summarizes recent advances in lipid-based systems for targeted delivery of AmB focusing on non-parenteral nanoparticulate formulations mainly investigated over the last five years and highlighting those that are currently in clinical trials.

show abstract

Section: Cochleatesmentioning

confidence: 94%

“…in a mouse model of systemic sporotrichosis and induced Th1/Th17 response with no significant changes in BUN and serum creatinine levels. [196] Nanodisk (ND)…”

Section: Lipid Conjugatesmentioning

confidence: 99%

Section: Cochleatesmentioning

confidence: 99%

See 1 more Smart Citation

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

2020

View full text Add to dashboard Cite

show abstract

“…These studies evidenced the enormous potential of these natural preparations as alternative treatment against sporotrichosis (Johann et al, 2007;Apisariyakul et al, 1995;Stopiglia et al, 2011;Gaitán et al, 2011;Singh et al, 2008;Masoko et al, 2005Masoko et al, , 2010Waller et al, 2016). In addition, some recent evidences suggest that association of immunomodulation and the antifungal effect can improve the efficacy of the sporotrichosis treatment (Guterres et al, 2014;Batista-Duharte et al, 2016).…”

Section: Introductionmentioning

confidence: 95%

“…The limited number of treatment options, joint to the increasing frequency of cross-resistance, makes necessary to develop new therapeutic strategies against fungal invasive infections. Some of these strategies are based in the improving of the antifungal effect and the stimulation of the immune response Batista-Duharte et al, 2016). Many efforts have been made to evaluate the antifungal properties of different medicinal plants with the hope of discovering new and more efficient antifungal compounds as therapeutic alternative to classic chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Anti-inflammatory activity of Vismia guianensis (Aubl.) Pers. extracts and antifungal activity against Sporothrix schenckii

Oliveira

Neto

et al. 2017

Journal of Ethnopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

Future Directions for Clinical Respiratory Fungal Research

Armstrong‐James

2021

Mycopathologia

View full text Add to dashboard Cite

There has been a growing appreciation of the importance of respiratory fungal diseases in recent years, with better understanding of their prevalence as well as their global distribution. In step with the greater awareness of these complex infections, we are currently poised to make major advances in the characterization and treatment of these fungal diseases, which in itself is largely a consequence of post-genomic technologies which have enabled rational drug development and a path towards personalized medicines. These advances are set against a backdrop of globalization and anthropogenic change, which have impacted the world-wide distribution of fungi and antifungal resistance, as well as our built environment. The current revolution in immunomodulatory therapies has led to a rapidly evolving population at-risk for respiratory fungal disease. Whilst challenges are considerable, perhaps the tools we now have to manage these infections are up to this challenge. There has been a welcome acceleration of the antifungal pipeline in recent years, with a number of new drug classes in clinical or pre-clinical development, as well as new focus on inhaled antifungal drug delivery. The “post-genomic” revolution has opened up metagenomic diagnostic approaches spanning host immunogenetics to the fungal mycobiome that have allowed better characterization of respiratory fungal disease endotypes. When these advances are considered together the key challenge is clear: to develop a personalized medicine framework to enable a rational therapeutic approach.

show abstract

Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii

Abstract: AFCo3-AmB exhibited a significant immunomodulator action, reduced toxicity and improved antifungal action against S. schenckii, suggesting a potential use as AmB delivery for systemic sporotrichosis treatment.

Cited by 24 publications

References 44 publications

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

Anti-inflammatory activity of Vismia guianensis (Aubl.) Pers. extracts and antifungal activity against Sporothrix schenckii

Future Directions for Clinical Respiratory Fungal Research

Contact Info

Product

Resources

About